A pen notebook and a calculator
Markets

Mead Johnson Nutrition’s Target, Estimates Cut at Goldman Sachs (MJN)

Pediatric nutrition specialist Mead Johnson Nutrition Co. ( MJN ) on Friday saw its price target and earnings estimates lowered by analysts at Goldman Sachs.

The firm said it now expects MJN shares to reach $74, suggesting a nearly 8% upside to the stock's Thursday closing price of $68.76.

Goldman maintained its "Neutral" rating on MJN but cut its earnings estimates, citing product safety concerns. On Thursday, news broke that Wal-Mart ( WMT ) had pulled the company's popular Enfamil formula from its shelves following the death of a Missouri child as from a bacterial infection. Later in the day, it was revealed that a second child had contracted the same illness, but it's still unclear whether or not either child was affected by tainted formula.

Mead Johnson shares posted modest gains in premarket trading Friday.

The Bottom Line

Shares of Mead Johnson Nutrition ( MJN ) have a 1.51% dividend yield, based on last night's closing stock price of $68.76. The stock has technical support in the $61-$65 price area. If the stock can firm up, we see overhead resistance around the all-time highs of $76-$77 a share.

Mead Johnson Nutrition Co. ( MJN ) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Created by Dividend.com


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

Stocks

Latest Markets Videos